Omero Benedicto Poli, Julio Cesar Rosa E Silva, Carlos Alberto Petta, Carlos Augusto Pires Costa Lino, Eduardo Schor, Helizabet Salomão Abdalla Ayroza Ribeiro, João Nogueira, João Sabino Lahorgue da Cunha, Marcia Cristina França, Márcia Mendonça Carneiro, Marco Aurélio Pinho de Oliveira, Marcos Tcherniakovsky, Maurício Simões Abrão, Raquel Papandreus Dib, Ricardo de Almeida Quintairos, Sergio Podgaec, Sidney Pearce
{"title":"Use of oral neuromodulators in chronic pelvic painNumber 8 - 2025.","authors":"Omero Benedicto Poli, Julio Cesar Rosa E Silva, Carlos Alberto Petta, Carlos Augusto Pires Costa Lino, Eduardo Schor, Helizabet Salomão Abdalla Ayroza Ribeiro, João Nogueira, João Sabino Lahorgue da Cunha, Marcia Cristina França, Márcia Mendonça Carneiro, Marco Aurélio Pinho de Oliveira, Marcos Tcherniakovsky, Maurício Simões Abrão, Raquel Papandreus Dib, Ricardo de Almeida Quintairos, Sergio Podgaec, Sidney Pearce","doi":"10.61622/rbgo/2025FPS8","DOIUrl":null,"url":null,"abstract":"<p><p>•Chronic pelvic pain is a common and complex condition that significantly affects women's quality of life. •Neuropathic pain and nociplastic pain are important components in the pain picture of these patients and should be considered in clinical treatment. •Oral neuromodulators, antidepressants and anticonvulsants for the control of neuropathic and nociplastic pain should be present in the therapeutic arsenal of the gynecologist who treats patients with chronic pelvic pain. •Pregabalin is the medication with the best pharmacokinetic profile; nortriptyline has the best adverse effects profile; duloxetine is the most widely used and has the lowest risks; and venlafaxine should be used as a second-line inhibitor. •Although the drug classes can be combined to reduce the total doses and minimize side effects, maximizing the analgesic effect, monotherapies are recommended as the first line to avoid polypharmacy.</p>","PeriodicalId":74699,"journal":{"name":"Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia","volume":"47 ","pages":""},"PeriodicalIF":1.4000,"publicationDate":"2025-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12671683/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.61622/rbgo/2025FPS8","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
•Chronic pelvic pain is a common and complex condition that significantly affects women's quality of life. •Neuropathic pain and nociplastic pain are important components in the pain picture of these patients and should be considered in clinical treatment. •Oral neuromodulators, antidepressants and anticonvulsants for the control of neuropathic and nociplastic pain should be present in the therapeutic arsenal of the gynecologist who treats patients with chronic pelvic pain. •Pregabalin is the medication with the best pharmacokinetic profile; nortriptyline has the best adverse effects profile; duloxetine is the most widely used and has the lowest risks; and venlafaxine should be used as a second-line inhibitor. •Although the drug classes can be combined to reduce the total doses and minimize side effects, maximizing the analgesic effect, monotherapies are recommended as the first line to avoid polypharmacy.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
